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Introduction {#ene13952-sec-0005}
============

Mitochondrial disorders are genetic diseases caused by mutations in nuclear encoded or mitochondrial DNA (mtDNA) encoded genes that impair oxidative phosphorylation, with resultant reduced ATP generation. The adult prevalence is approximately 1 in 4300 [1](#ene13952-bib-0001){ref-type="ref"}, ranking mitochondrial diseases amongst the most commonly inherited neurological disorders. Central neurological and neuromuscular phenotypes predominate in adults given the high energy requirements of the nervous system. Gastrointestinal (GI) symptoms are common [2](#ene13952-bib-0002){ref-type="ref"} and are cardinal features of mitochondrial neurogastrointestinal encephalomyopathy [3](#ene13952-bib-0003){ref-type="ref"} and an important manifestation of the m.3243A\>G *MT‐TL1* mtDNA mutation [4](#ene13952-bib-0004){ref-type="ref"}. Given that mitochondrial GI symptoms are likely to be underpinned by impaired oxidative phosphorylation within the smooth musculature or autonomic nervous system, there is a high probability that the genitourinary tract is impaired by similar pathophysiological mechanisms. However, systematic evaluation of lower urinary tract symptoms (LUTS) and sexual dysfunction has not been undertaken in genetically confirmed mitochondrial disease.

A large case--control study has therefore been undertaken to determine the frequency, profile and potential pathophysiological mechanisms underpinning LUTS and sexual dysfunction in adults with genetically confirmed mitochondrial disease.

Methods {#ene13952-sec-0006}
=======

Study population {#ene13952-sec-0007}
----------------

Adults (aged ≥ 18 years) with genetically confirmed mitochondrial disease attending our specialist mitochondrial disorders clinic, alongside age and gender matched control subjects (partners, unaffected relatives or friends of patients), were recruited. Demographic and clinical data, including genotype, time from diagnosis and medications, were collected. For patients harbouring the m.3243A\>G *MT‐TL1* mutation blood heteroplasmy level and the presence/absence of diabetes mellitus (DM) were recorded. The Newcastle Mitochondrial Disease Adult Scale (NMDAS) score [5](#ene13952-bib-0005){ref-type="ref"} was completed as part of routine clinical assessments. The study was approved by the Queen Square Research Ethics Committee, London (09/H0716/76), and informed consent was obtained.

Assessment of lower urinary tract symptoms, sexual dysfunction and bowel symptoms {#ene13952-sec-0008}
---------------------------------------------------------------------------------

Lower urinary tract symptoms, sexual dysfunction and bowel symptoms were evaluated using four validated, self‐administered questionnaires: (i) the Urinary Symptom Profile (USP) [6](#ene13952-bib-0006){ref-type="ref"}; (ii) the SF‐Qualiveen (SFQ) [7](#ene13952-bib-0007){ref-type="ref"}; (iii) the Arizona Sexual Experiences Scale (ASEX) [8](#ene13952-bib-0008){ref-type="ref"}; and (iv) the Neurogenic Bowel Dysfunction (NBD) score [9](#ene13952-bib-0009){ref-type="ref"}.

The USP scores three symptom domains: stress urinary incontinence (SUI, 0--9); overactive bladder (OAB, 0--21); and low stream (LS, 0--9) (higher score indicating greater severity). The presence/absence of global LUTS (total USP score \>0 or 0, respectively), domain LUTS (individual USP sub‐score \>0 or 0, respectively) and symptom severity (sub‐score) for each of the three domains was analysed. The SFQ is validated for use in neurological patients and assesses LUTS‐related quality of life (QoL). A higher score indicates greater impact on QoL. The presence of any impact on QoL (score \> 0) and its severity (total score) were analysed in those with symptoms detected by the USP. The ASEX evaluates sexual dysfunction. It comprises five questions, with the last two completed only by individuals sexually active within the last week. The presence or absence of recent sexual activity and sexual dysfunction were analysed. The NBD comprises 10 questions concerning bowel function. The presence/absence of symptoms (score ≥1 or 0 respectively) was analysed.

Urodynamic studies {#ene13952-sec-0009}
------------------

Urodynamic studies (UDS) were undertaken in a subset of patients with symptoms identified using the USP questionnaire, to further characterize the LUTS and guide management. These comprised non‐invasive uroflowmetry, measurement of post‐void residual (PVR) volumes and invasive multichannel UDS, including filling cytometry (medium fill at 50 ml/min) and pressure‐flow studies (Medical Measurement Systems, Dover, NH, USA) following International Continence Society Good Urodynamic Practices.

Data description and statistical analysis were performed according to data type (Data [S1](#ene13952-sup-0001){ref-type="supplementary-material"}, Supporting Information).

Results {#ene13952-sec-0010}
=======

Demographics {#ene13952-sec-0011}
------------

Eighty‐eight genetically confirmed mitochondrial disease patients were offered two questionnaires, one for the patient and one to enable them to recruit an unaffected control subject. Questionnaires from 58 patients (mean age 46.2 ± 14.9 years, 67.2% female) and 19 age/sex matched control subjects (mean age 44 ± 13.5 years, 47.4% female; age *P* = 0.581, sex *P* = 0.121; Fig. [S1](#ene13952-sup-0001){ref-type="supplementary-material"}, Tables [1](#ene13952-tbl-0001){ref-type="table"} and [S1](#ene13952-sup-0001){ref-type="supplementary-material"}) were completed. The average time from diagnosis was 9.6 ± 8.7 years. The m.3243A\>G *MT‐TL1* mutation was the most common genotype in the patient cohort (26/58, 44.8%). Fifty‐three patients (91.4%) harboured pathogenic mutations in mtDNA.

###### 

Demographic and molecular characteristics of the study population

  -----------------------------------------------------------------------------------------
                          Patients    Controls      *P* value                 
  ----------------------- ----------- ------------- ----------- ------------- -------------
  All                     58          46.2 (14.9)   19          44.0 (13.5)   Age: 0.581

  Females                 39 (67.2)   46.4 (15.3)   9 (47.4)    42.0 (13.3)   Age: 0.466

  Males                   19 (32.8)   45.9 (14.1)   10 (52.6)   45.6 (13.4)   Age: 0.959\
                                                                              Sex: 0.121

  mtDNA genotype          53 (91.4)                                           

  m.3243A\>G              26 (44.8)   51.1 (14.2)   19          44.0 (13.5)   Age: 0.111

  Single mtDNA deletion   12 (20.7)   41.8 (17.5)   19          44.0 (13.5)   Age: 0.705

  m.8344A\>G              5 (8.6)                                             

  m.3260A\>G              2 (3.4)                                             

  m.9185T\>C              2 (3.4)                                             

  mtDNA duplication       2 (3.4)                                             

  Other mtDNA mutation    4 (6.9)                                             

  nDNA genotype           5 (8.6)                                             

  *POLG*                  2 (3.4)                                             

  Other nDNA mutation     3 (5.2)                                             
  -----------------------------------------------------------------------------------------

mtDNA, mitochondrial DNA; nDNA, nuclear DNA.
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Lower urinary tract symptoms {#ene13952-sec-0012}
----------------------------

The USP detected LUTS in 41/49 (83.7%) patients compared with 11/16 (68.8%) controls (*P* = 0.030; Figs [1](#ene13952-fig-0001){ref-type="fig"} and [S2](#ene13952-sup-0001){ref-type="supplementary-material"}, Table [2](#ene13952-tbl-0002){ref-type="table"}). Forty‐four (44/54, 81.5%) patients experienced OAB symptoms, 20/58 (34.5%) LS symptoms and 15/52 (28.8%) SUI symptoms. Patients were significantly more likely to experience OAB (*P* = 0.039) and LS (*P* = 0.013) symptoms but not SUI symptoms (*P* = 0.109), with significantly higher scores (OAB *P* = 0.023 and LS *P* = 0.050) compared with controls. There was an impact on QoL from symptoms in 24/41 (58.5%) patients with LUTS, which was comparable with controls (Table [S2](#ene13952-sup-0001){ref-type="supplementary-material"}). Female patients were more likely to have LUTS (29/33, 87.9% vs. 3/7, 42.9%, *P* = 0.007), particularly OAB symptoms (32/37, 86.5% vs. 2/7, 28.6%, *P* = 0.001), than female controls and their OAB symptoms were more severe (*P* = 0.013). No statistically significant differences were detected in the other USP domains or between male patients and controls.

![Urinary symptoms across domains of the Urinary Symptom Profile in adults with mitochondrial disease and controls. (a)--(c) Presence of symptoms in the total population and subgroups. (d)--(f) Severity of symptoms in the total population and subgroups demonstrating significant findings. LS, low stream; OAB, overactive bladder; SUI, stress urinary incontinence. \**P* \< 0.05.](ENE-26-1111-g001){#ene13952-fig-0001}

###### 

Presence and severity of urinary symptoms across Urinary Symptom Profile domains in adults with mitochondrial diseases and controls

  USP domain    Patients   Controls    *P* value presence   *P* value severity                                                                                                                                                     
  ------------- ---------- ----------- -------------------- -------------------- --------- ----- ----------- ----------- ----- --------------------------------------------------- ----------------------------------------------- -----------------------------------------------
  All domains   All        49          41 (83.7)                                           All   16          11 (68.8)                                                             0.030[\*](#ene13952-note-0003){ref-type="fn"}   
  Females       33         29 (87.9)                                             Females   7     3 (42.9)                      0.007[\*\*](#ene13952-note-0003){ref-type="fn"}                                                     
  Males         16         12 (75.0)                                             Males     9     8 (88.9)                      0.405                                                                                               
  m.3243A\>G    20         18 (90.0)                                             All       16    11 (68.8)                     0.109                                                                                               
  OAB           All        54          44 (81.5)            3.5                  6         All   16          9 (56.3)    1     3                                                   0.039[\*](#ene13952-note-0003){ref-type="fn"}   0.023[\*](#ene13952-note-0003){ref-type="fn"}
  Females       37         32 (86.5)   4                    6                    Females   7     2 (28.6)    0           1.5   0.001[\*\*\*](#ene13952-note-0003){ref-type="fn"}   0.013[\*](#ene13952-note-0003){ref-type="fn"}   
  Males         17         12 (70.6)   3                    6                    Males     9     7 (77.8)    1           2     0.694                                               0.659                                           
  m.3243A\>G    23         20 (87.0)   6                    5.25                 All       16    9 (56.3)    1           3     0.031[\*](#ene13952-note-0003){ref-type="fn"}       0.018[\*](#ene13952-note-0003){ref-type="fn"}   
  LS            All        58          20 (34.5)            0                    1         All   19          1 (5.3)     0     0                                                   0.013[\*](#ene13952-note-0003){ref-type="fn"}   0.050[\*](#ene13952-note-0003){ref-type="fn"}
  Females       39         12 (30.8)   0                    1                    Females   9     0 (0.0)     0           0     0.055                                               0.089                                           
  Males         19         8 (42.1)    0                    1.5                  Males     10    2 (20.0)    0           0     0.234                                               0.322                                           
  m.3243A\>G    26         12 (46.2)   0                    1.75                 All       19    1 (5.3)     0           0     0.003[\*\*](#ene13952-note-0003){ref-type="fn"}     0.016[\*](#ene13952-note-0003){ref-type="fn"}   
  SUI           All        52          15 (28.8)            0                    1         All   19          2 (10.5)    0     0                                                   0.109                                           0.079
  Females       34         13 (38.2)   0                    1                    Females   9     2 (22.2)    0           0     0.370                                               0.272                                           
  Males         18         2 (11.1)    0                    0                    Males     10    0 (0.0)     0           0     0.274                                               0.524                                           
  m.3243A\>G    22         8 (36.4)    0                    1                    All       19    2 (10.5)    0           0     0.055                                               0.049[\*](#ene13952-note-0003){ref-type="fn"}   

IQR, interquartile range; LS, low stream; Mdn, median; *n*, number; OAB, overactive bladder; SUI, stress urinary incontinence. Presence of symptoms indicated by Urinary Symptom Profile (USP) score in each domain \>0; severity of symptoms as indicated by total USP score in each domain. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001, at four decimal places.
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Urodynamic studies {#ene13952-sec-0013}
------------------

Uroflowmetry (*n* = 10) showed an abnormal flow pattern in eight patients. Mean maximum flow rate (*Q* ~max~) was 18.3 ml/s (range 4.3--36.7; reduced flow rate \< 15 ml/s, *n* = 6). Mean PVR was 49.0 ml (range 0--345 ml). Six patients underwent invasive UDS. Abnormal findings in filling cystometry included detrusor overactivity (*n* = 2), increased bladder sensations (*n* = 3; detrusor overactivity in 2), reduced bladder sensations (*n* = 3), and increased total bladder capacity (*n* = 3). A pressure‐flow study showed abnormalities (*n* = 4) and none showed an obstructed flow (Table [3](#ene13952-tbl-0003){ref-type="table"}).

###### 

Uroflowmetry and invasive urodynamics in adults with mitochondrial disease

  Gender   Age (years)   Confirmed mutation         Uroflowmetry   Urodynamics: filling cystometry   Urodynamics: pressure flow study                                                                         
  -------- ------------- -------------------------- -------------- --------------------------------- ---------------------------------- ------ ------ ------ ---- --- ------ ----- -------------- ------ ---- ------
  Female   42            m.3302A\>G                 305            Irregular                         31.6                               0      362↑   467    −    N   650↑   650   Irregular      32     27   0
  Male     64            Multiple mtDNA deletions   272            Prolonged                         4.3↓                               345↑   574↑   637↑   −    N   722↑   22    Strain         2↓     0↓   700↑
  Male     78            m.3243A\>G                 195            Irregular                         14.6↓                              0      235↑   451    −    N   499    586   Intermittent   7.8↓   22   0
  Female   40            m.3243A\>G                 180            Irregular                         12↓                                0      61↓    122↓   \+   N   83↓    †                                
  Female   58            m.3260A\>G                 145            Smooth                            10↓                                40     104↓   105↓   \+   N   194    †                                
  Female   62            m.14674T\>C                342            Intermittent                      36.7                               16     62↓    182↓   −    N   601↑   ‡                                
  Female   59            Single deletion            222            Smooth                            23.4                               0                                                                     
  Male     26            m.9185T\>C                 300            Intermittent                      31.1                               0                                                                     
  Male     32            m.9185T\>C                 188            Intermittent                      11.2↓                              47                                                                    
  Male     52            m.3243A\>G                 115            Irregular                         7.6↓                               42                                                                    

DO, detrusor overactivity; FSV, bladder volume at first sensation; N, normal; NDV, bladder volume at normal desire to void; Pdet, maximum detrusor pressure; *Q* ~max~, maximum flow rate; +, positive; −, negative; †, not recorded because of severe DO; ‡, patient unable to void; ↓, decreased below the reference range; ↑, increased above the reference range.
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Sexual dysfunction {#ene13952-sec-0014}
------------------

Fifty‐one patients completed the ASEX questionnaire. Twenty‐two (43.1%) were sexually active within the previous week and 24 (47.1%) experienced sexual dysfunction. No differences in sexual activity or the presence of sexual dysfunction were detected between patients and controls (*P* = 0.271 and *P* = 0.100, respectively). Fewer female patients than controls had been sexually active (13/32, 40.6% vs. 7/9, 77.8%, *P* = 0.049) and more experienced sexual dysfunction (17/32, 53.1% vs. 1/9, 11.1%, *P* = 0.026). No difference was observed between rates of sexual activity or sexual dysfunction in males compared with controls (Fig. [2](#ene13952-fig-0002){ref-type="fig"}, Table [4](#ene13952-tbl-0004){ref-type="table"}).

![Sexual activity (a), sexual dysfunction (b) and bowel symptoms (c) in adults with mitochondrial disease and controls. \**P* \< 0.05, \*\**P* \< 0.01.](ENE-26-1111-g002){#ene13952-fig-0002}

###### 

Sexual activity, sexual dysfunction and bowel symptoms in adults with mitochondrial disease and controls

  Patient group   Control group   Sexually active *P* value   Sexual dysfunction *P* value   Bowel symptoms *P* value                                                                                                                                              
  --------------- --------------- --------------------------- ------------------------------ -------------------------- -------------- ------------- ------------- ----------------------------------------------- ----------------------------------------------- -------------------------------------------------
  All             22/51 (43.1)    24/51 (47.1)                28/55 (50.9)                   All                        11/19 (57.9)   5/19 (26.3)   3/18 (16.7)   0.271                                           0.100                                           0.011[\*](#ene13952-note-0005){ref-type="fn"}
  Females         13/32 (40.6)    17/32 (53.1)                20/38 (52.6)                   Females                    7/9 (77.8)     1/9 (11.1)    3/8 (37.5)    0.049[\*](#ene13952-note-0005){ref-type="fn"}   0.026[\*](#ene13952-note-0005){ref-type="fn"}   0.437
  Males           12/19 (63.2)    6/19 (31.6)                 8/17 (47.1)                    Males                      6/10 (60.0)    4/10 (40.0)   0/10 (0.0)    0.868                                           0.650                                           0.010[\*\*](#ene13952-note-0005){ref-type="fn"}
  m.3243A\>G      9/21 (42.9)     14/21 (66.7)                15/24 (62.5)                   All                        11/19 (57.9)   5/19 (26.3)   3/18 (16.7)   0.342                                           0.011[\*](#ene13952-note-0005){ref-type="fn"}   0.003[\*\*](#ene13952-note-0005){ref-type="fn"}

*n*, number. Sexual activity within the last week and sexual dysfunction as indicated by the Arizona Sexual Experiences Scale. Bowel symptoms as indicated by a Neurogenic Bowel Dysfunction score \>0. \**P* \< 0.05; \*\**P* \< 0.01, at four decimal places.
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Bowel symptoms {#ene13952-sec-0015}
--------------

Significantly more patients had bowel symptoms than controls (28/55, 50.9% vs. 3/18, 16.7%, *P* = 0.011; Fig. [2](#ene13952-fig-0002){ref-type="fig"}, Table [4](#ene13952-tbl-0004){ref-type="table"}) and 29.8% (17/57) of patients reported bowel opening two to six times a week or less, compared with 3.5% (2/57) who experienced faecal incontinence.

Relationship between lower urinary tract symptoms, sexual dysfunction and bowel symptoms {#ene13952-sec-0016}
----------------------------------------------------------------------------------------

Bowel symptoms and sexual dysfunction coexisted in patients (*P* = 0.011), but there was no association between LUTS (USP global or domain scores) and sexual or bowel dysfunction.

Disease burden and lower urinary tract symptoms, sexual dysfunction and bowel symptoms {#ene13952-sec-0017}
--------------------------------------------------------------------------------------

The scaled NMDAS score (*n* = 56) was significantly higher in patients with LUTS compared to without (median 16.7 vs. 7.3, *P* = 0.033). There was a significant correlation between NMDAS and USP LS scores (*r* = 0.296, *P* = 0.027). However, no correlation was detected with the USP SUI or OAB sub‐scores (Fig. [S3](#ene13952-sup-0001){ref-type="supplementary-material"}) and there was no difference in NMDAS score in patients with and without sexual (*P* = 0.080) or bowel dysfunction (*P* = 0.364).

Treatments for lower urinary tract symptoms, sexual dysfunction and bowel symptoms {#ene13952-sec-0018}
----------------------------------------------------------------------------------

Compared to controls, no patients were receiving treatment for LUTS (controls 2/19, 10.5% vs. patients 0/58, 0.0%, *P* = 0.012). The proportions of patients and controls on treatment for bowel (5/58, 8.6% vs. 0/19, 0.0%, *P* = 0.186) or sexual dysfunction symptoms (4/58, 6.9% vs. 2/19, 10.5%, *P* = 0.609) were comparable (Table [S3](#ene13952-sup-0001){ref-type="supplementary-material"}).

Genotype‐specific findings: the m.3243A\>G *MT‐TL1* mutation {#ene13952-sec-0019}
------------------------------------------------------------

Patients harbouring the m.3243A\>G *MT‐TL1* mutation (*n* = 26) had more OAB (*P* = 0.031) and LS (*P* = 0.003) symptoms than controls, and scored higher in all three USP domains (OAB *P* = 0.018, LS *P* = 0.016, SUI *P* = 0.049; Fig. [1](#ene13952-fig-0001){ref-type="fig"}, Table [2](#ene13952-tbl-0002){ref-type="table"}) although, on removal of the outlier, significance in the SUI domain was lost (*P* = 0.103). Sexual activity was comparable with controls (*P* = 0.342), but patients were more likely to experience sexual dysfunction (14/21, 66.7% vs. 5/19, 26.3%, *P* = 0.011). They were also more likely to have bowel symptoms (15/24, 62.5% vs. 3/18, 16.7%, *P* = 0.003; Fig. [2](#ene13952-fig-0002){ref-type="fig"}, Table [4](#ene13952-tbl-0004){ref-type="table"}).

Blood heteroplasmy levels were available for 17/26 patients with the m.3243A\>G *MT‐TL1* mutation. There was no significant positive correlation between blood heteroplasmy levels and domains of the USP (Fig. [S4](#ene13952-sup-0001){ref-type="supplementary-material"}). There was also no difference between heteroplasmy levels in those with or without sexual dysfunction (*P* = 0.325) or bowel symptoms (*P* = 0.101).

Eighteen patients with the m.3243A\>G *MT‐TL1* mutation had DM. There was no association between the presence of DM and LUTS (*P* = 0.515) and no difference between scores in individual domains of the USP in patients with and without DM (Fig. [S5](#ene13952-sup-0001){ref-type="supplementary-material"}). Sexual dysfunction (*P* = 0.655) and bowel symptoms (*P* = 0.132) were not associated with DM.

Discussion {#ene13952-sec-0020}
==========

Lower urinary tract symptoms are increasingly reported in inherited neurological disorders that involve the central and peripheral nervous systems [10](#ene13952-bib-0010){ref-type="ref"}, [11](#ene13952-bib-0011){ref-type="ref"}. However, limited data on LUTS in mitochondrial diseases exist [12](#ene13952-bib-0012){ref-type="ref"}, [13](#ene13952-bib-0013){ref-type="ref"}. The results of this study suggest that adults with genetically proven mitochondrial disease frequently experience LUTS (83.7%). In our cohort, OAB (storage) symptoms were the most common (81.5%), followed by LS (voiding) symptoms (34.5%) and SUI symptoms (28.8%), and OAB and LS symptoms were significantly more common in patients than controls. Sexual dysfunction was associated with mitochondrial disease in female patients and carriers of the m.3243A\>G *MT‐TL1* mutation (53.1% and 66.7% respectively). Bowel symptoms were more common in patients (50.9%) and were associated with sexual dysfunction.

The results of urodynamic testing in a representative number of patients from the cohort suggests that the lower urinary tract is affected in numerous ways in mitochondrial disorders, including effects on storage and voiding sensory and motor functions. Storage dysfunction was due to detrusor overactivity and increased bladder sensations. In neurological disorders, storage dysfunction occurs most frequently with suprasacral lesions [14](#ene13952-bib-0014){ref-type="ref"} and could be related to a central neurological phenotype in patients with mitochondrial disease, e.g. mitochondrial encephalomyopathy, lactic acidosis and stroke‐like episodes (MELAS). Detrusor overactivity has also been reported in other primary muscle disorders such as the dystrophinopathies [11](#ene13952-bib-0011){ref-type="ref"}. However, it remains uncertain whether detrusor overactivity in these disorders is associated with the myopathic presentation or additional central nervous system or autonomic involvement. Although both sexes experienced comparable levels of OAB symptoms, only females reported significantly more OAB symptoms, and of greater severity, compared to age/gender matched controls. This discrepancy may result from the high rates of storage symptoms in the male control population (Fig. [1](#ene13952-fig-0001){ref-type="fig"}) due to other causes, such as benign prostatic enlargement which is present in half of men over 50 [15](#ene13952-bib-0015){ref-type="ref"}. Sixty‐two questionnaires provided to control subjects were not returned, the explanation for which is probably multi‐factorial; for instance, the questionnaire might not have been passed on to the control subject by the patient or may not have been completed due to its sensitive nature or the absence of symptoms.

Voiding dysfunction, evidenced by an abnormal flow and/or elevated post‐void residual or detrusor underactivity in the pressure‐flow study, was observed in most patients. In neurological diseases this may arise from detrusor sphincter dyssynergia or an underactive detrusor [14](#ene13952-bib-0014){ref-type="ref"}. In our cohort, detrusor underactivity is likely to be an important cause based on the findings from four of the pressure‐flow studies. The cause for detrusor underactivity is unclear and could be due to involvement of the detrusor smooth muscle, the innervation of the lower urinary tract or diminished cellular energy production. Structural urological lesions such as benign prostatic enlargement cause voiding symptoms [14](#ene13952-bib-0014){ref-type="ref"}. However, the presence of symptoms in the all‐patient group, and lack of evidence for outflow obstruction in the patients undergoing urodynamic testing, implicates mitochondrial dysfunction. The apparent mismatch between the number of patients with voiding symptoms detected by the USP questionnaire and the high prevalence of voiding dysfunction in urodynamic testing (six of 10 cases) may be due to selection bias, given that only patients with significant LUTS agreed to undergo urodynamic testing. However, this also raises the possibility of asymptomatic voiding dysfunction.

Male sexual dysfunction has previously been evaluated in a questionnaire‐based screening study of autonomic function in MELAS and no significant difference with controls was detected [12](#ene13952-bib-0012){ref-type="ref"}. In our cohort, fewer female patients were sexually active than controls, and females and carriers of the m.3243A\>G *MT‐TL1* mutation experienced significantly more sexual dysfunction. However, the confounding effect of a chronic disease cannot be completely excluded [16](#ene13952-bib-0016){ref-type="ref"}.

Despite the high prevalence of LUTS and their impact on QoL, no patients were on treatment for these symptoms. Further studies are required to explore LUTS and sexual dysfunction in mitochondrial disease and the reasons underpinning the treatment gap observed. These are likely to be multi‐factorial, including a lack of awareness amongst healthcare professionals concerning LUTS in mitochondrial disease and reluctance for patients to discuss them. Given that several safe and effective treatments exist for LUTS in patients with neurological disease [14](#ene13952-bib-0014){ref-type="ref"}, in addition to potential management options for sexual dysfunction, it is important to establish the presence of these symptoms. However, caution is advised when commencing treatments for lower urinary tract storage symptoms, particularly antimuscarinic agents which are associated with an increased risk of developing voiding dysfunction and incomplete bladder emptying when subclinical voiding problems exist. It is recommended that the established investigative approach is followed for neurological patients [14](#ene13952-bib-0014){ref-type="ref"}.

Fifty‐one per cent of our patient cohort, and 62.5% of m.3243A\>G patients, had bowel symptoms, consistent with previous studies [2](#ene13952-bib-0002){ref-type="ref"}, [12](#ene13952-bib-0012){ref-type="ref"}. Male patients had significantly more bowel symptoms than same sex controls, a difference not seen in females. This may reflect the higher incidence of GI symptoms in females in the general population [17](#ene13952-bib-0017){ref-type="ref"}. Patients experienced more voiding difficulties (infrequent bowel opening, 29.8%) than faecal incontinence (3.5%) mirroring the higher prevalence of urinary voiding symptoms compared with SUI urinary symptoms.

Mitochondrial DM occurs in up to 42% of patients harbouring the m.3243A\>G *MT‐TL1* mutation [18](#ene13952-bib-0018){ref-type="ref"} and dysautonomia associated with DM is a well‐recognized cause of urinary tract, sexual and GI symptoms [19](#ene13952-bib-0019){ref-type="ref"}. However, no significant difference in these symptoms was seen in the m.3243A\>G patients with or without DM, suggesting that their symptoms relate directly to their mitochondrial disorder rather than diabetes, in keeping with data investigating the influence of diabetes on the GI manifestations of m.3243A\>G‐related mitochondrial disease [20](#ene13952-bib-0020){ref-type="ref"}.

Finally, total NMDAS scores correlated with LS but not OAB symptoms, whilst blood m.3243A\>G heteroplasmy levels demonstrated no significant positive association with LUTS, sexual dysfunction or bowel symptoms. These findings might imply that disease burden does not influence the emergence of dysfunction, but might also reflect the challenges of using the NMDAS, originally designed to record longitudinal natural history data in individuals with mitochondrial disease, when comparing patients with heterogeneous clinical phenotypes [5](#ene13952-bib-0005){ref-type="ref"}. The results also emphasize the limited value of heteroplasmy levels, in particular when undertaken in blood rather than urinary epithelial cells or skeletal muscle tissue, when measuring disease severity [21](#ene13952-bib-0021){ref-type="ref"}.

In conclusion, the first cohort study of LUTS and sexual dysfunction in adults with mitochondrial disease is reported. It is confirmed that LUTS are common and impact QoL, and that female patients and those with the m.3243A\>G *MT‐TL1* mutation experience sexual dysfunction. Bladder storage symptoms predominate, although voiding dysfunction may occur subclinically. Despite several effective treatments for LUTS in neurological diseases, none of the patients was receiving therapy for these, thus emphasizing the importance of active screening, investigation and appropriate interventions to improve management of adults with mitochondrial disease.
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